Your browser doesn't support javascript.
loading
Application of ATP-tumor chemosensitivity assay in recurrent epithelial ovarian cancer / 中华肿瘤杂志
Chinese Journal of Oncology ; (12): 855-858, 2010.
Artigo em Chinês | WPRIM | ID: wpr-293466
ABSTRACT
<p><b>OBJECTIVE</b>To explore the value of adenosine triphosphate-tumor chemosensitivity assay (ATP-TCA) in individualized treatment of recurrent epithelial ovarian cancer (REOC), and to evaluate the correlation between the in vitro chemosensitivity assay and clinical drug sensitivity.</p><p><b>METHODS</b>Sixty-nine REOC specimens were tested by ATP-TCA assay retrospectively. The patients were divided into strong sensitive, moderate sensitively and resistant groups according to the ATP-TCA assay results. The clinical results were evaluated according to imaging and serum CA125 analysis. The correlation between in vitro ATP-TCA assay and clinical outcome was statistically analyzed by χ(2) test. The progression free survival (PFS) and overall survival (OS) of each group were analyzed using Kaplan-Meier method.</p><p><b>RESULTS</b>The results of ATP-TCA assay had significant correlation with clinical outcome. The clinical chemotherapy outcome became better with increased drug sensitivity in vitro (χ(2) = 9.066, P = 0.004). The sensitivity, specificity, positive predictive value, negative predictive value and accuracy rate for ATP-TCA method to predict the clinical chemotherapy sensitivity of REOC were 87.5%, 45.9%, 58.3%, 80.9% and 65.2%, respectively. The mean PFS of strong sensitive group, moderately sensitive group and resistant group were 187.1 days, 195.0 days and 60.3 days, respectively. The mean OS were 476.7, 335.7 and 237.5 days, respectively, following the start of TCA-directed therapy. The PFS and OS of the two sensitivity groups in vitro were significantly longer than that of the in vitro-resistant group (P < 0.01).</p><p><b>CONCLUSION</b>The results of ATP-TCA assay are well correlated with clinical treatment responses. The assay may be an important and useful method for individualized chemotherapy for recurrent ovarian cancer.</p>
Assuntos
Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Neoplasias Ovarianas / Sangue / Ensaios de Seleção de Medicamentos Antitumorais / Protocolos de Quimioterapia Combinada Antineoplásica / Doxorrubicina / Trifosfato de Adenosina / Taxa de Sobrevida / Valor Preditivo dos Testes / Estudos Retrospectivos / Seguimentos Tipo de estudo: Estudo diagnóstico / Estudo observacional / Estudo prognóstico / Fatores de risco Limite: Feminino / Humanos Idioma: Chinês Revista: Chinese Journal of Oncology Ano de publicação: 2010 Tipo de documento: Artigo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Neoplasias Ovarianas / Sangue / Ensaios de Seleção de Medicamentos Antitumorais / Protocolos de Quimioterapia Combinada Antineoplásica / Doxorrubicina / Trifosfato de Adenosina / Taxa de Sobrevida / Valor Preditivo dos Testes / Estudos Retrospectivos / Seguimentos Tipo de estudo: Estudo diagnóstico / Estudo observacional / Estudo prognóstico / Fatores de risco Limite: Feminino / Humanos Idioma: Chinês Revista: Chinese Journal of Oncology Ano de publicação: 2010 Tipo de documento: Artigo